2min chapter

Post Reports cover image

The promise and peril of ketamine

Post Reports

CHAPTER

Navigating FDA Approval and Off-Label Use of Ketamine for Mental Health

This chapter explores the FDA's cautious approach to ketamine for mental health, focusing on obstacles related to its off-patent status and the implications for clinical trials. It contrasts the unregulated off-label use with the stricter approval process for S-ketamine, emphasizing patient experiences alongside regulatory hurdles.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode